Better Ways to Target Pain

Improved understanding of the chemical pathway on which aspirin and Vioxx act may lead to analgesics with fewer side effects

Join Our Community of Science Lovers!


On supporting science journalism

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.


Bengt Samuelsson won the Nobel Prize in Physiology or Medicine in 1982 for his work on providing an exacting picture of how the body generates prostaglandins. These hormonelike substances play a role in regulating various biological processes, including the pain induction, fever and inflammation that are blocked by aspirin, ibuprofen and related drugs. Samuelsson did his research, along with Sune Bergstr?m, another of that year's co-winners, on the red-brick campus of Sweden's Karolinska Institute, which also selects the annual Nobel medicine prize.

Karolinska has a long history with prostaglandins, one that dates back to the discovery of these fatty acid derivatives in 1935 and extends up to the present day. In recent years Samuelsson and his collaborators have further elucidated prostaglandin biochemistry--research that is now being exploited in an attempt to develop painkillers and anti-inflammatory drugs that are safer than existing agents, including the now tarnished group known as COX-2 inhibitors. "There's an enormous demand for anti-inflammatory drugs," Samuelsson notes. "And if we can develop a drug that's as effective as previous drugs with fewer side effects, that's very important."

Gary Stix is the former senior editor of mind and brain topics at Scientific American.

More by Gary Stix
Scientific American Magazine Vol 296 Issue 1This article was published with the title “Better Ways to Target Pain” in Scientific American Magazine Vol. 296 No. 1 ()
doi:10.1038/scientificamerican012007-56c2jAv5l57eUbTNBhOfMJ

It’s Time to Stand Up for Science

If you enjoyed this article, I’d like to ask for your support. Scientific American has served as an advocate for science and industry for 180 years, and right now may be the most critical moment in that two-century history.

I’ve been a Scientific American subscriber since I was 12 years old, and it helped shape the way I look at the world. SciAm always educates and delights me, and inspires a sense of awe for our vast, beautiful universe. I hope it does that for you, too.

If you subscribe to Scientific American, you help ensure that our coverage is centered on meaningful research and discovery; that we have the resources to report on the decisions that threaten labs across the U.S.; and that we support both budding and working scientists at a time when the value of science itself too often goes unrecognized.

In return, you get essential news, captivating podcasts, brilliant infographics, can't-miss newsletters, must-watch videos, challenging games, and the science world's best writing and reporting. You can even gift someone a subscription.

There has never been a more important time for us to stand up and show why science matters. I hope you’ll support us in that mission.

Thank you,

David M. Ewalt, Editor in Chief, Scientific American

Subscribe